Overall Score

Growth

Revenue base remains modest at a 0.51x price-to-sales ratio, but profitability is still negative with a -12.4% net margin and -9.6% operating margin.

Asset efficiency is only fair, with 0.64x asset turnover and 2.65x fixed-asset turnover, limiting long-term compounding potential.

Profitability

Gross margin is only 17.0%, and operating performance remains negative with -5.2% EBITDA margin and -10.3% EBIT margin.

Returns are deeply negative across the board, including -20.9% ROE, -7.2% ROIC, and -8.0% ROA.

Financial Health

Liquidity is acceptable but not strong, with a 1.29 current ratio and 0.40 quick ratio, while cash ratio is only 0.03.

Leverage is elevated relative to earnings power, with debt-to-equity at 1.30x and net debt-to-EBITDA not meaningful because EBITDA is negative.

Cash Flow

Cash generation is weak, with negative operating cash flow and free cash flow, reflected in -19.7x price-to-operating-cash-flow and -8.4x price-to-free-cash-flow.

Capex is consuming cash rather than being funded by it, as capex-to-operating-cash-flow is -1.36x and free cash flow per share is -2.92.

Valuation

Valuation looks inexpensive on sales and book value, with 0.51x price-to-sales and 0.98x price-to-book.

However, the apparent cheapness is offset by negative earnings and cash flow, making traditional earnings-based multiples less informative.